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Abstract
Melioidosis, caused by the environmental saprophyte, Burkholderia pseudomallei, is an important public health problem in 
Southeast Asia and Northern Australia. It is being increasingly reported from other parts, including India, China, and North and 
South America expanding the endemic zone of the disease. We report a case of systemic melioidosis in a 58-year-old diabetic, 
occupationally-unexposed male patient, who presented with chronic fever, sepsis, pneumonia, pleural effusion and subcuta-
neous abscess, was undiagnosed for long, misidentified as Pseudomonas aeruginosa infection elsewhere, but was saved due 
to correct identification of the etiologic agent and timely institution of appropriate therapy at our institute. A strong clinical and 
microbiological suspicion for melioidosis should be considered in the differential diagnosis of acute pyrexia of unknown origin, 
acute respiratory distress syndrome and acute onset of sepsis, especially in the tropics. 
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Introduction
Melioidosis or “the remarkable imitator”, an 
acute infectious disease, caused by the environ-
mental Gram-negative bacillus, Burkholderia 
pseudomallei, is endemic, widespread and an 
important public health problem in Southeast 
Asia and Northern Australia [1, 2]. It is being in-
creasingly reported from other parts of the world, 
including India, China, Sri Lanka, and North and 
South America expanding the endemic zone of 
the disease [3, 4]. 
We report a case of melioidosis in a diabetic, 
occupationally unexposed male, who presented 
with chronic fever, sepsis, pneumonia, pleural 
effusion and subcutaneous abscess, was undia-
gnosed for long, misidentified as Pseudomonas 
aeruginosa infection elsewhere, but was saved 
due to correct identification of the etiologic agent 
and timely institution of appropriate therapy at 
our institute.
Case 
 A-58-year-old male, office employee, was 
admitted to our hospital in mid-September 2015 
with a history of unremittent high-grade fever 
with intermittent cough and expectoration for 
3 months, a progressively increasing swelling 
on posterior left chest wall for two months, 
right-sided pleuritic chest pain for one month, 
and shortness of breath for 2 weeks. He had de-
creased appetite and progressive loss of weight 
for the past one month. He was a known diabetic 
since 20 years managed with oral hypoglycaemic 
agents. There was no history of travel outside his 
place of residence in the preceding 6 months of 
his onset of symptoms. However, when probed, 
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the patient provided a history of renovation of his 
toilet 15 days prior to the onset of symptoms, for 
which he was going to open fields for defecation, 
though with proper footwear.
Prior to his admission at our hospital, he had 
consulted four different hospitals and received 
several broad-spectrum antibiotics including car-
bapenems and antipseudomonal antibiotics based 
on the culture isolate of Pseudomonas auerogino-
sa in the diagnostic pus aspirate from the chest 
wall swelling performed in the hospital he visited 
last. Empirical antitubercular therapy was also 
started in one of the hospitals, but was discon-
tinued after a few days owing to gastrointestinal 
toxicity. Thus, despite a reasonable duration of 
antimicrobial therapy, he remained febrile with 
high temperature spikes (> 39°C) and his general 
condition progressively worsened.
Physical examination revealed a thin-built 
anemic man, conscious, but too sick and debili-
tated to take interest in the surrounding. He had 
weight loss of 7 kg since the start of his symptoms. 
Admission vital parameters were deranged with 
heart rate 120/min, blood pressure 108/66 mm Hg, 
respiratory rate 26/min, oral temperature 40.0°C 
and oxygen saturation of 96% at room air. Patient 
had a pyogenic extra-thoracic abscess of 7 × 4 
cm at left infra-scapular area. Chest auscultation 
revealed diminished breath sounds in right basal 
area with inspiratory crackles. Other systemic 
findings were normal. 
Laboratory investigations
Total leucocyte count was 16.91 × 109/l (93% 
polymorphs, 6% lymphocytes, 1 % monocytes), 
total red blood cell count 2.9 × 1012/l, platelet 
count 185 × 109/l and haemoglobin 65 g/l. Blood 
metabolic panel suggested poor diabetes control 
(random blood sugar 381 mg/dl, fasting blood 
glucose 260 mg/dl, postprandial blood sugar 274 
mg/dL), with urea 26 mg/dl and creatinine 1mg/dl. 
Serum electrolytes and liver function tests were 
within normal limits except for a low serum al-
bumin level of 1.4 g/dl.
Contrast enhanced computed tomogram (CT) 
of the thorax showed bilateral pleural effusions (ri-
ght more than left), and left chest wall abscess witho-
ut any pleuro-abscess communication (Fig. 1A). 
Soft-tissue window showed mediastinal lym-
phadenopathy and bilateral peripheral lung 
nodules with cavitations consistent with sep-
tic pulmonary emboli (Fig. 1B). A diagnosis of 
septicaemic bronchopneumonia with bilateral 
pleural effusions was made. Aseptically drained 
pus along with blood, urine, sputum, and pleural 
fluid (1.5 ml, right side aspirate) were subjected to 
microbiological investigations, including culture. 
The patient was commenced on empiric therapy 
with parenteral antibiotics (ceftazidime, 2 gm IV 
8-hourly, and levofloxacin 750 mg IV once-daily) 
as these antibiotics were not used earlier.
Blood peripheral smear demonstrated micro-
cytic hypochromic anaemia without any parasites 
or abnormal cells. Sputum smear examination for 
acid-fast bacilli was negative. Gram stain of the 
pus aspirate showed polymorphs (6−8 per oil 
immersion field) and few gram-negative bacilli. 
Microscopy and biochemistry of the pleural fluid 
aspirate were supportive of an exudate (total leu-
cocyte count — 1250 cells per cubic millimetre; 
50% polymorphs; protein 2.5 g/dl; glucose 130 
mg/dl; Lactate dehydrogense 230 IU/l). Culture 
of the pus, blood, and pleural fluid aspirate yiel-
ded pure growth of small, smooth, non-lactose 
fermenting colonies on MacConkey’s agar after 
overnight incubation, which turned pink with a 
metallic sheen after 48 hours and dry and wrin-
kled after 96 hours of incubation (Fig. 2A). Blood 
agar grew small, greyish white, smooth, non-ha-
emolytic colonies after overnight incubation, 
Figure 1. Contrast-enhanced chest CT showing (A) bilateral pleural effusions (right more than left) and left chest wall abscess without any pleuro-
-abscess communication, and (B) mediastinal lymphadenopathy with bilateral peripheral lung nodular opacities with cavitation
A B
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Figure 2. Identification of Burkholderia pseudomallei by (A) Growth on Mac Conkey agar, (B) Growth on Blood Agar, (C) “Safety pin” appearance 
on Gram stain, and (D)Biochemical reactions
Figure 3. Antibiotic susceptibility of Burkholderia pseudomallei de-
monstrating (A) resistance to Polymyxin B 300U (PB) and colistin 
10µg (CL) disks, and (B) Ceftazidime MIC (3µg/ml ) by Etest
A B
C D
A Bwhich subsequently changed over to large, flat, 
dry, and wrinkled with central umbonation after 
96 hours of incubation (Fig. 2B). Microscopy from 
culture revealed motile, Gram negative bacilli 
with typical bipolar staining giving a “safety-pin” 
appearance (Fig. 2C). The isolates were subsequ-
ently identified as B. pseudomallei by standard 
biochemical tests (positive oxidase and nitrate 
reduction test, positive arginine dihydrolase ac-
tivity, positive citrate utilisation test, oxidative 
utilization of glucose, lactose, maltose, growth 
at 42° C, and negative lysine decarboxylase re-
action) and by their resistance to colistin 10µg, 
gentamicin 10µg, and polymyxin B 300U disks 
(Figs 2D, 3A). Minimum inhibitory concentration 
of various antibiotics by Etest (bioMérieux, Marcy 
l’Etoile, France) showed the isolates to be sensiti-
ve to ceftazidime, co-trimoxazole, imipenem, me-
ropenem, and amoxicillin- clavulanate (Table 1, 
Fig. 3B) [5].
Once the culture report was available, cefta-
zidime was continued as intensive therapy (2 gm 
IV 8-hourly) for a prolonged duration of 3 weeks 
followed by weight-based oral cotrimoxazole 
(Trimethoprim 240 mg and Sulfamethoxazole 
1200 mg) twice daily as maintenance therapy. 
Glycemic control alongwith correction of ane-
mia and hypoalbuminemia was optimized with 
insulin therapy and transfusion of packed red 
blood cells and fresh frozen plasma respectively. 
Clinical improvement was noted within a week of 
ceftazidime therapy. A repeat blood culture after 
seven days of ceftazidime therapy was sterile. 
The patient was discharged from the hospital on 
24th day of admission with advice to continue 
cotrimoxazole for at least six months. On the last 
review visit, the patient was totally asymptomatic 
with complete recovery from the lesion.
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Table 1. Minimum inhibitory concentration (MIC) of antimicrobial agents for the isolates of Burkholderia pseudomallei [5] 
Antimicrobial agent MIC (µg/ml)  MIC interpretative criteria, for susceptible (s), intermediate (i), and resistant (r),
CLSI M45-A2 
Ceftazidime 3 s ≤ 8, i 16, r ≥ 32
Cotrimoxazole 2 s ≤ 2/38, −, r ≥ 4/76
Imipenem 2 s ≤ 4, i 8, r ≥ 16 
Meropenem 2 s ≤ 4, i 8, r ≥ 16
Amoxicillin-clavulanate 4 s ≤ 8/4, i 16/8, r ≥ 32/16
Discussion
Melioidosis was first recognized as a clinical 
entity in 1911 when Indian Bacteriologist C.S. 
Krishnaswami, under the guidance of the patho-
logist Alfred Whitmore described a “Glanders-like 
disease” among the morphine addicts and vaga-
bonds found dead in the streets of Rangoon (Yan-
gon), Burma (Myanmar) [6]. The first indigenous 
report of melioidosis from India was by Raghavan 
et al., from Mumbai in 1991 [7]. Since then, cases 
of human melioidosis have been reported from 
several Indian states [8].
Humans acquire the infection by inhalation 
of contaminated dust or droplets, ingestion of 
contaminated water, or contact with contami-
nated soil especially through skin abrasions 
[1, 2]. People with occupational or recreational 
exposure to moist soil or surface water such as 
rice farmers, other agricultural workers, building 
site labourers, adventure travellers, soldiers and 
immigrants are at greatest risk [1, 4]. Nearly 75 to 
81% of cases occur during the rainy season [4]. 
The incubation period may range from days to 
many years; generally symptoms appear 2−4 
weeks after exposure [1, 4]. The disease can re-
main dormant for years and can activate many 
years after the initial exposure, causing diagnostic 
confusion [9]. Additionally, the causative agent 
displays inherent resistance to most of the com-
monly used antibiotics, penicillin, ampicillin, 
first-generation and second-generation cephalo-
sporins, gentamicin, tobramycin, streptomycin, 
and even to polymyxin; limiting the treatment 
options [4]. 
Although healthy people may get melio-
idosis, the major risk factors include diabetes, 
heavy alcohol use, chronic pulmonary disease, 
chronic renal disease, thalassemia, glucocorticoid 
therapy, and cancer [3]. The causative bacterium 
is widely present in soil up to a depth of 25−45 
cms in the endemic regions. Their movement to 
the surface with the rising water table during the 
rainy seasons has been proposed responsible for 
its increased transmission rates [10]. Our patient 
was diabetic and developed infection in the rainy 
season, but was without occupational exposure 
to soil or water. It is possible, however, that he 
acquired the infection either by percutaneous 
inoculation by minor trivial trauma or aerosoli-
sation of bacteria during exposure to the ongoing 
household construction work or use of open field 
for defecation.
The clinical spectrum of B. pseudomallei in-
fection is extremely broad, ranging from asympto-
matic infection, localized skin ulcers or abscesses, 
chronic pneumonia mimicking tuberculosis, and 
fulminant septic shock with abscesses in multiple 
internal organs [2−4]. Acute sepsis is the most 
serious, accounting for up to 60% of infections. 
Bacteremic dissemination is frequent and pre-
sents as multifocal pneumonia, subcutaneous 
abscesses, abscesses in solid abdominal visceral 
organs, septic arthritis, osteomyelitis, and septi-
caemia. On chest radiographs, diffuse nodular in-
filtrates often develop throughout both lungs and 
they coalesce, cavitate, and progress rapidly, to 
caseous necrosis and multiple metastatic abscess 
formation [3, 11, 12]. Mortality rate can reach as 
high as 95% in absence of effective intervention, 
and 50% even after antibiotic therapy [3, 12].
The remaining 40% patients have localised 
infections, most frequently in the lung (manife-
sting as mild bronchitis to severe pneumonia), 
and abscesses or granulomata in any organ system 
like cutaneous and subcutaneous abscesses, lym-
phadenitis, osteomyelitis, septic arthritis, liver 
and/or splenic abscesses, cystitis, pyelonephritis, 
prostatic abscesses, epididymo-orchitis, and brain 
abscesses [3, 8]. As evident, the clinical symptoms 
of melioidosis mimic those of many other dise-
ases; thus, differentiating between melioidosis 
and other acute and chronic bacterial infections, 
including tuberculosis, is often difficult. Many 
patients presenting with prolonged fever, weight 
loss, and suspicious chest radiographic findings, 
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are misdiagnosed as tuberculosis and may get 
anti-tubercular therapy [13] as in the present case. 
Around 11% of the cases present with chronic 
melioidosis defined as illness with symptoms for 
longer than 2 months’ duration on presentation 
[3, 4]. Fifteen percent of chronic melioidosis cases 
present with pleural effusion [14]. The present 
case had acute septicaemic melioidosis, with 
widespread dissemination to lung (pneumonia) 
and subcutaneous tissue (abscess), remained 
undiagnosed for long, and subsequently progres-
sed to chronic pleural involvement with pleural 
effusion. The CT thorax showing widespread 
bilateral peripheral lung nodular opacities bears 
evidence to disseminated ‘blood-borne pneumo-
nia’ in the present case. 
In tropics, melioidosis should be considered 
in the differential diagnosis of acute pyrexia of 
unknown origin, acute respiratory distress syndro-
me and acute onset of sepsis, especially if presen-
ting during rainy season, if multiple pustular or 
necrotic skin or subcutaneous lesions develop, or 
if there is a radiologic pattern of tuberculosis from 
which tubercle bacilli cannot be demonstrated. 
A delay in diagnosis can be fatal, since empirical 
antibiotic regimens used for suspected bacterial 
sepsis often do not provide adequate coverage for 
B. pseudomallei. However, a delay in the identi-
fication of B. pseudomallei or a misidentification 
as another species (most commonly, Pseudomonas 
species or as a contaminant in culture) is not un-
common in laboratories that are unfamiliar with 
this organism [15]. It is extremely important to 
monitor the patients for at least one year after com-
pletion of therapy because of the risk of recurrence. 
Recurrent melioidosis occurs in approximately 1 in 
16 patients, often in the first year after the initial 
presentation. Roughly a quarter of recurrences 
are due to reinfection, with the remainder due to 
relapse from a persistent focus of infection [4]. 
In October 2012, B. pseudomallei was upgra-
ded to a Tier 1 Select Agent by the Centers for 
Disease Control and Prevention resulting in incre-
ased research and understanding of melioidosis 
[3]. With the expansion of endemic zone of the 
disease into previously considered non-endemic 
regions, high degree of suspicion and vigilance on 
the part of both microbiologists and clinicians is 
need of the hour for an early and accurate detec-
tion of the organism and decreasing case fatality. 
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